Business Description
![Syros Pharmaceuticals Inc Syros Pharmaceuticals Inc logo](https://static.gurufocus.com/logos/0C0000B4BT.png?14)
Syros Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US87184Q2066
Description
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.3 | |||||
Equity-to-Asset | -0.06 | |||||
Debt-to-Equity | -9.55 | |||||
Debt-to-EBITDA | -0.49 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -12.79 | |||||
Beneish M-Score | -4.39 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -52.5 | |||||
3-Year EBITDA Growth Rate | 31.4 | |||||
3-Year EPS without NRI Growth Rate | 37.6 | |||||
3-Year FCF Growth Rate | 33.5 | |||||
3-Year Book Growth Rate | -66.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 41.59 | |||||
Future 3-5Y Total Revenue Growth Rate | 220.12 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 18.46 | |||||
9-Day RSI | 18.6 | |||||
14-Day RSI | 21.5 | |||||
6-1 Month Momentum % | -14.86 | |||||
12-1 Month Momentum % | 49.46 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.46 | |||||
Quick Ratio | 3.46 | |||||
Cash Ratio | 3.22 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -67.6 | |||||
Shareholder Yield % | 3.75 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -2835.68 | |||||
Net Margin % | -3171.7 | |||||
FCF Margin % | -2657.33 | |||||
ROE % | -487.6 | |||||
ROA % | -89.09 | |||||
ROIC % | -324.23 | |||||
ROC (Joel Greenblatt) % | -633.23 | |||||
ROCE % | -108.24 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 11.29 | |||||
EV-to-EBIT | -0.21 | |||||
EV-to-EBITDA | -0.21 | |||||
EV-to-Revenue | 6.32 | |||||
EV-to-Forward-Revenue | 27.93 | |||||
EV-to-FCF | -0.24 | |||||
Earnings Yield (Greenblatt) % | -476.19 | |||||
FCF Yield % | -249.92 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Syros Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 3.879 | ||
EPS (TTM) (€) | -4.016 | ||
Beta | 2.12 | ||
Volatility % | 167.85 | ||
14-Day RSI | 21.5 | ||
14-Day ATR (€) | 0.276542 | ||
20-Day SMA (€) | 3.43 | ||
12-1 Month Momentum % | 49.46 | ||
52-Week Range (€) | 1.35 - 7.26 | ||
Shares Outstanding (Mil) | 26.81 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Syros Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Syros Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Syros Pharmaceuticals Inc Frequently Asked Questions
What is Syros Pharmaceuticals Inc(STU:0S90)'s stock price today?
The current price of STU:0S90 is €1.47. The 52 week high of STU:0S90 is €7.26 and 52 week low is €1.35.
When is next earnings date of Syros Pharmaceuticals Inc(STU:0S90)?
The next earnings date of Syros Pharmaceuticals Inc(STU:0S90) is 2024-11-14 Est..
Does Syros Pharmaceuticals Inc(STU:0S90) pay dividends? If so, how much?
Syros Pharmaceuticals Inc(STU:0S90) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |